Business Context and Reporting Period
Company: Armour Residential REIT, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2025
Principal Event: Entry into a Material Definitive Agreement (Amendment No. 5 to Equity Sales Agreement).
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Corporate Actions
- Equity Sales Program Expansion: The Company entered into Amendment No. 5 to its Equity Sales Agreement with multiple sales agents (including BUCKLER Securities, B. Riley Securities, and others).
- Share Increase: The number of shares of Common Stock available for sale under the "at-the-market" (ATM) offering program was increased by 15,000,000 shares.
- Total Availability: Under the Amended Sales Agreement, the Company may now issue and sell up to 24,049,403 shares of Common Stock. This total comprises 9,049,403 shares remaining from prior amendments plus the new 15,000,000 shares.
- Registration: The shares are offered pursuant to a prospectus supplement filed on February 13, 2025, under an effective shelf registration statement (Form S-3, No. 333-278327).
Guidance, Outlook, and Risks
Management Commentary: The filing states the purpose of the amendment was to increase the number of shares available under the Sales Agreement. No specific financial guidance or outlook was provided in this document.
Risks and Contingencies: The filing includes a standard disclaimer that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration or qualification. A legal opinion regarding the validity of the shares to be issued is attached as Exhibit 5.1.
Investor Verification Checklist
- Verify the total number of shares remaining available for sale under the ATM program (24,049,403) against the Company's current outstanding share count to assess potential dilution.
- Review the attached Exhibit 1.1 (Amendment No. 5) for specific terms regarding sales agent commissions and pricing mechanisms.
- Monitor future filings to determine the actual volume and timing of shares sold under this expanded program.
- Confirm the status of the Company's shelf registration statement (No. 333-278327) to ensure it remains effective for future offerings.